BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15288254)

  • 1. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.
    Mazitschek R; Giannis A
    Curr Opin Chem Biol; 2004 Aug; 8(4):432-41. PubMed ID: 15288254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
    Mendel DB; Laird AD; Smolich BD; Blake RA; Liang C; Hannah AL; Shaheen RM; Ellis LM; Weitman S; Shawver LK; Cherrington JM
    Anticancer Drug Des; 2000 Feb; 15(1):29-41. PubMed ID: 10888034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
    Kim DW; Lu B; Hallahan DE
    Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
    Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
    J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of growth factor antagonists with antiangiogenic and antitumor properties.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6566-73. PubMed ID: 11426641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth factor receptor kinase inhibitors: recent progress and clinical impact.
    Dumas J
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):378-89. PubMed ID: 11727303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM
    Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer].
    Leirdal M; Sioud M
    Tidsskr Nor Laegeforen; 2002 Jan; 122(2):178-82. PubMed ID: 11873574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: IMC-1C11, ImClone Systems.
    Hunt S
    Curr Opin Mol Ther; 2001 Aug; 3(4):418-24. PubMed ID: 11525567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapeutic approaches in glioblastomas].
    Le Guilloux J; Carpentier AF
    Rev Neurol (Paris); 2008; 164(6-7):554-9. PubMed ID: 18565354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining molecular therapeutics with radiotherapy for head and neck cancer.
    Riesterer O; Milas L; Ang KK
    J Surg Oncol; 2008 Jun; 97(8):708-11. PubMed ID: 18493923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting growth factors and angiogenesis; using small molecules in malignancy.
    Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
    Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.